The New Jersey Medical Marijuana Review Panel has issued initial recommendations to add several new qualifying conditions to the state’s medical marijuana program: chronic pain related to musculoskeletal disorders or of visceral origin, migraine, anxiety, and Tourette’s Syndrome. There will now be a 60-day public comment period, after which the Panel will consider the comments and hold another meeting before making its final recommendations.
Related: Bill to Regulate Marijuana Introduced in New Jersey
If you are a New Jersey resident suffering from one of these conditions who could benefit from access to medical cannabis, we encourage you to submit public comments via email or mail. Mailed comments must be postmarked by Monday, September 25, 2017, and sent to:
NJ Department of Health, Medicinal Marijuana Program
Attn: Medicinal Marijuana Review Panel
PO Box 360
Trenton, NJ 08625-0360
In other good news, the sixth Alternative Treatment Center permitted under New Jersey law has finally been issued a permit to begin cultivating medical cannabis! It will be located in Secaucus.
About the Author: Kate Bell acts as Legislative Counsel in the State Policies Department at the Marijuana Policy Project. Founded in 1995, Marijuana Policy Project is the largest advocacy organization in the United States that's sole focus is ending marijuana prohibition.